Myasthenia gravis: diagnostic, prognostic, and treatment response markers

Recruiting

Conditions: G70
Myasthenia gravis and other myoneural disorders

Registration Number: DRKS00024428

Lead Sponsor: Klinik für NeurologieNeuroCure Clinical Research Center (NCRC)Charité Universitätsmedizin BerlinCharité Campus Mitte

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 1600

Inclusion Criteria

Inclusion criteria Myasthenia patients:
- Confirmed diagnosis of myasthenia gravis.
- Men and women
- Ability to give consent
- Written informed consent

Inclusion criteria Controls:
- Men and women
- Capacity to consent
- Written informed consent

Group 1: age-matched, no neurological diseases with motor impairments, no autoimmunological diseases, no depression.
Group 2: age-matched, other neuroimmunological diseases (e.g. multiple sclerosis, immune neuropathies)

Exclusion Criteria

General Exclusion Criteria:
- Lack of communication skills
- Alcohol or drug abuse (current)

Study & Design

Study Type: observational

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Identification of risk factors as well as predictive biomarkers (immune markers, gene markers) in the early course of the disease (<12 months after first symptom) for progression (pure ocular, generalized or myasthenic crisis within 36 months).<br>The planned study is a mixed prospective and retrospective observational study.<br>Many parameters (antibody status, imaging of the thymus) are part of routine clinical diagnostics for MG patients. <br>A special clinical examination (Q-motor), which allows quantification of motor functions by means of instrumental diagnostics, is used. The aim of this Q-motor examination is to compare its results with the results of the current diagnostic standard, the Besinger Score. In addition, it is a goal to use a very sensitive method to determine to what extent patients who are clinically assessed as having ocular progression do not have signs of generalization that are difficult to recognize.

Secondary Outcome Measures

Name	Time	Method
Identification of markers for response to specific therapies and for long-term disease progression, as well as for specific MG-specific findings through the systematic collection and analysis of the parameters described above.